Ibis Biosciences' innovative molecular technology will change the traditional approach to infectious disease testing. The goal is to develop a platform that can rapidly identify a broad range of infectious organisms, without knowing beforehand which organisms might be present in a sample.
New Infectious Disease Testing Vision
Abbott is expanding its role in molecular infectious disease testing. Acquired in 2009, Ibis is focused on delivering an innovative approach to detect and characterize pathogens. Current efforts are underway to develop a new robust instrument for the clinical laboratory that is designed to detect and identify a broad range of bacteria, viruses and fungi.Developing a system designed to provide actionable answers in one laboratory shift, direct from a patient specimen.
- Start empiric antimicrobial therapies
- Culture Positive
+ gram strain - Biochemical ID
- Antibiotic resistance
- Change to targeted therapies
WEEK 1
Goal: Ibis Technology actionable results
Change to targeted therapies- Start empiric antimycotic therapy
- Culture and ID:
Change to targeted
therapies
WEEK 1
Goal: Ibis Technology actionable results
Change to targeted therapies